Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.
Marcia S. Brose
Consultant or Advisory Role - Bayer; Onyx
Honoraria - Bayer
Research Funding - Bayer
Barbara Jarzab
Honoraria - Bayer
Rossella Elisei
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Salvatore Siena
No relevant relationships to disclose
Lars Bastholt
Consultant or Advisory Role - Bayer (U)
Honoraria - Bayer
Christelle De La Fouchardiere
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Furio Pacini
Consultant or Advisory Role - Bayer
Ralf Paschke
Other Remuneration - Bayer
Christopher Nutting
Honoraria - Bayer
Young Kee Shong
No relevant relationships to disclose
Steven I. Sherman
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Eisai; Exelixis; Pfizer; Roche
Honoraria - Bayer; Exelixis
Research Funding - Amgen
Other Remuneration - Exelixis
Johannes WA Smit
No relevant relationships to disclose
John Woojune Chung
Employment or Leadership Position - Bayer
Christian Kappeler
Employment or Leadership Position - Bayer Schering Pharma
Istvan Molnar
Employment or Leadership Position - Bayer
Martin Schlumberger
Consultant or Advisory Role - AstraZeneca; Bayer; Eisai; Genzyme
Honoraria - AstraZeneca; Bayer; Eisai; Genzyme; SOBI
Research Funding - AstraZeneca; Bayer; Eisai; Genzyme